Verastem Reports Positive Early Data for KRAS Cancer Drug VS-7375

Dow Jones

06/24

By Anvee Bhutani

Verastem Oncology reported positive early-stage data for its experimental cancer drug VS-7375, which is being developed to treat cancers driven by KRAS G12D mutations.

The company said the drug showed anti-tumor activity in patients with pancreatic, colorectal and lung cancers, while maintaining a favorable safety profile.

Among pancreatic cancer patients receiving a higher dose of the drug, 93% saw a significant reduction in a key tumor marker, according to the company.

Verastem said side effects were mostly mild gastrointestinal issues, such as nausea and diarrhea, and generally improved after the first treatment cycle.

The company also said it plans to evaluate VS-7375 in combination with an experimental cancer treatment being developed by Erasca.

Verastem expects to provide another update on the program later this year.

Write to Anvee Bhutani at anvee.bhutani@wsj.com

(END) Dow Jones Newswires

June 23, 2026 16:25 ET (20:25 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2645585906"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2645585906\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2645585906?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-24 04:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645585906","market":"nz","top_or_hot":-1,"title":"Verastem Reports Positive Early Data for KRAS Cancer Drug VS-7375","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Anvee Bhutani \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/VSTM\">Verastem</a> Oncology reported positive early-stage data for its experimental cancer drug VS-7375, which is being developed to treat cancers driven by KRAS G12D mutations. \n</p>\n<p>\n  The company said the drug showed anti-tumor activity in patients with pancreatic, colorectal and lung cancers, while maintaining a favorable safety profile. \n</p>\n<p>\n  Among pancreatic cancer patients receiving a higher dose of the drug, 93% saw a significant reduction in a key tumor marker, according to the company. \n</p>\n<p>\n  Verastem said side effects were mostly mild gastrointestinal issues, such as nausea and diarrhea, and generally improved after the first treatment cycle. \n</p>\n<p>\n  The company also said it plans to evaluate VS-7375 in combination with an experimental cancer treatment being developed by Erasca. \n</p>\n<p>\n  Verastem expects to provide another update on the program later this year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Anvee Bhutani at anvee.bhutani@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 23, 2026 16:25 ET (20:25 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Verastem Reports Positive Early Data for KRAS Cancer Drug VS-7375</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVerastem Reports Positive Early Data for KRAS Cancer Drug VS-7375\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-24 04:25</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Anvee Bhutani \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/VSTM\">Verastem</a> Oncology reported positive early-stage data for its experimental cancer drug VS-7375, which is being developed to treat cancers driven by KRAS G12D mutations. \n</p>\n<p>\n  The company said the drug showed anti-tumor activity in patients with pancreatic, colorectal and lung cancers, while maintaining a favorable safety profile. \n</p>\n<p>\n  Among pancreatic cancer patients receiving a higher dose of the drug, 93% saw a significant reduction in a key tumor marker, according to the company. \n</p>\n<p>\n  Verastem said side effects were mostly mild gastrointestinal issues, such as nausea and diarrhea, and generally improved after the first treatment cycle. \n</p>\n<p>\n  The company also said it plans to evaluate VS-7375 in combination with an experimental cancer treatment being developed by Erasca. \n</p>\n<p>\n  Verastem expects to provide another update on the program later this year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Anvee Bhutani at anvee.bhutani@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 23, 2026 16:25 ET (20:25 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VSTM","symbol_name":"Verastem","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2645585906","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2645585906","pubTimestamp":1782246300,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Verastem Oncology reported positive early-stage data for its experimental cancer drug VS-7375, which is being developed to treat cancers driven by KRAS G12D mutations.The company said the drug showed anti-tumor activity in patients with pancreatic, colorectal and lung cancers, while maintaining a favorable safety profile.Among pancreatic cancer patients receiving a higher dose of the drug, 93% saw a significant reduction in a key tumor marker, according to the company.Verastem said side effects were mostly mild gastrointestinal issues, such as nausea and diarrhea, and generally improved after the first treatment cycle.The company also said it plans to evaluate VS-7375 in combination with an experimental cancer treatment being developed by Erasca.Verastem expects to provide another update on the program later this year.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VSTM":"Verastem","BK4085":"互动家庭娱乐","VS":"Versus Systems Inc.","BK4139":"生物科技"},"translate_title":"Verastem报告KRAS抗癌药物VS-7375的积极早期数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VSTM":1.5,"VS":1.5},"content_text":"By Anvee Bhutani \n\n\n \n\n\nVerastem Oncology reported positive early-stage data for its experimental cancer drug VS-7375, which is being developed to treat cancers driven by KRAS G12D mutations. \n\n\n  The company said the drug showed anti-tumor activity in patients with pancreatic, colorectal and lung cancers, while maintaining a favorable safety profile. \n\n\n  Among pancreatic cancer patients receiving a higher dose of the drug, 93% saw a significant reduction in a key tumor marker, according to the company. \n\n\n  Verastem said side effects were mostly mild gastrointestinal issues, such as nausea and diarrhea, and generally improved after the first treatment cycle. \n\n\n  The company also said it plans to evaluate VS-7375 in combination with an experimental cancer treatment being developed by Erasca. \n\n\n  Verastem expects to provide another update on the program later this year. \n\n\n \n\n\n  Write to Anvee Bhutani at anvee.bhutani@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 23, 2026 16:25 ET (20:25 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}